On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Cassidy RJ, Liu Y, Patel K, Zhong J, Steuer CE, Kooby DA, et al. Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: analysis of the National Cancer Database. Cancer. 2016. [Epub ahead of print]. doi:10.1002/cncr30410
   Google Scholar
• Cameron MG, Kersten C, Vistad I, Fossa S, Guren MG. Palliative pelvic radiotherapy of symptomatic incurable rectal cancer – a systematic review. Acta Oncol. 2014;53:164–73.
   PubMed Web of Science ®Google Scholar
• Cameron MG, Kersten C, Vistad I, van Helvoirt R, Weyde K, Undseth C, et al. Palliative pelvic radiotherapy for symptomatic rectal cancer – a prospective multicenter study. Acta Oncol. 2016;55:1400–7.
   PubMed Web of Science ®Google Scholar
• Glimelius B. Optimal time intervals between pre-operative radiotherapy or chemoradiotherapy and surgery in rectal cancer? Front Oncol. 2014;4:50.
   PubMedGoogle Scholar
• Glimelius B. Multidisciplinary treatment of patients with rectal cancer: development during the past decades and plans for the future. Ups J Med Sci. 2012;117:225–36.
   PubMed Web of Science ®Google Scholar
• Maringe C, Walters S, Rachet B, Butler J, Finan P, Morris E, et al. Optimal use of staging data in international comparisons of colorectal cancer survival. Acta Oncol. 2014;53:847–8.
   PubMed Web of Science ®Google Scholar
• Guren MG, Korner H, Pfeffer F, Myklebust TA, Eriksen MT, Edna TH, et al. Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010. Acta Oncol. 2015;54:1714–22.
   PubMed Web of Science ®Google Scholar
• Iversen LH, Green A, Ingeholm P, Osterlind K, Gogenur I. Improved survival of colorectal cancer in Denmark during 2001–2012 – The efforts of several national initiatives. Acta Oncol. 2016;55(Suppl 2):10–23.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Tiret E, Cervantes A, Arnold D, Group EGW. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi81–8.
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23:2479–516.
   PubMed Web of Science ®Google Scholar
• Swedish National Colorectal Cancer Care Programme. Regional Cancer Centre North, Umeå. Available at: http://www.cancercentrum.se/globalassets/cancerdiagnoser/tjock–och-andtarm/vardprogram/nvpkolorektalcancer_2016-03-15.pdf. (accessed 1 Nov 2016).
   Google Scholar
• Taylor F, Mangat N, Swift IR, Brown G. Proforma-based reporting in rectal cancer. Cancer Imaging. 2010;10(Spec no A):S142–S50.
   Google Scholar
• Taylor FG, Quirke P, Heald RJ, Moran BJ, Blomqvist L, Swift IR, et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol. 2014;32:34–43.
   PubMed Web of Science ®Google Scholar
• Battersby NJ, How P, Moran B, Stelzner S, West NP, Branagan G, et al. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II Study. Ann Surg. 2016;263:751–60.
   PubMed Web of Science ®Google Scholar
• Brannstrom F, Bjerregaard JK, Winbladh A, Nilbert M, Revhaug A, Wagenius G, et al. Multidisciplinary team conferences promote treatment according to guidelines in rectal cancer. Acta Oncol. 2015;54:447–53.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Isacsson U, Jung B, Påhlman L. Radiotherapy in addition to radical surgery in rectal cancer: evidence for a dose-response effect favouring preoperative treatment. Int J Radiat Oncol Biol Phys. 1997;37:281–7.
   PubMed Web of Science ®Google Scholar
• Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336:980–7.
   PubMed Web of Science ®Google Scholar
• Kapiteijn E, Marijnen CAM, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy in combination with total mesorectal excision improves local control in resectable rectal cancer. Report from a multicenter randomized trial. N Engl J Med. 2001;345:638–46.
   PubMed Web of Science ®Google Scholar
• Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811–20.
   PubMed Web of Science ®Google Scholar
• Birgisson H, Påhlman L, Gunnarsson U, Glimelius B. Late adverse effects of radiation therapy for rectal cancer - a systematic overview. Acta Oncol. 2007;46:504–16.
   PubMed Web of Science ®Google Scholar
• Joye I, Verstraete J, Bertoncini C, Depuydt T, Haustermans K. Implementation of volumetric modulated arc therapy for rectal cancer: pitfalls and challenges. Acta Oncol. 2015;54:1677–81.
   PubMed Web of Science ®Google Scholar
• Bujko K, Kolodziejczyk M. The 5 x 5 Gy with delayed surgery in non-resectable rectal cancer: a new treatment option. Radiother Oncol. 2008;87:311–13.
   PubMed Web of Science ®Google Scholar
• Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with t3 rectal cancer: trans-tasman radiation oncology group trial 01.04. J Clin Oncol. 2012;30:3827–33.
   PubMed Web of Science ®Google Scholar
• Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26:303–12.
   PubMed Web of Science ®Google Scholar
• Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23.
   PubMed Web of Science ®Google Scholar
• Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620–5.
   PubMed Web of Science ®Google Scholar
• Braendengen M, Tveit KM, Berglund Å, Birkemeyer E, Frykholm G, Påhlman L, et al. A randomized phase III study (LARCS) comparing preoperative radiotherapy alone versus chemoradiotherapy in non-resectable rectal cancer. J Clin Oncol. 2008;26:3687–94.
   PubMed Web of Science ®Google Scholar
• Radu C, Berglund Å, Påhlman L, Glimelius B. Short course preoperative radiotherapy with delayed surgery in rectal cancer – a retrospective study. Radiother Oncol. 2008;87:343–9.
   PubMed Web of Science ®Google Scholar
• Hatfield P, Hingorani M, Radhakrishna G, Cooper R, Melcher A, Crellin A, et al. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol. 2009;92:210–14.
   PubMed Web of Science ®Google Scholar
• Pettersson D, Holm T, Iversen H, Blomqvist L, Glimelius B, Martling A. Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. Br J Surg. 2012;99:577–83.
   PubMed Web of Science ®Google Scholar
• Tiv M, Puyraveau M, Mineur L, Calais G, Maingon P, Bardet E, et al. Long-term quality of life in patients with rectal cancer treated with preoperative (chemo)-radiotherapy within a randomized trial. Cancer Radiother. 2010;14:530–4.
   PubMed Web of Science ®Google Scholar
• Braendengen M, Tveit KM, Bruheim K, Cvancarova M, Berglund A, Glimelius B. Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized phase III study. Int J Radiat Oncol Biol Phys. 2011;81:1017–24.
   PubMed Web of Science ®Google Scholar
• Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15:184–90.
   PubMed Web of Science ®Google Scholar
• Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer: the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2015;16:979–89.
   PubMed Web of Science ®Google Scholar
• Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28:1638–44.
   PubMed Web of Science ®Google Scholar
• Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773–80.
   PubMed Web of Science ®Google Scholar
• O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32:1927–34.
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Haustermans K, Price T, Nordlinger B, Hofheinz RD, Daisne JF, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine + oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: early results of the PETACC 6 trial. Proc Am Soc Clin. 2014;32:abstr 3501.
   Google Scholar
• Glimelius B. Is the benefit of oxaliplatin in rectal cancer clinically relevant? Lancet Oncol. 2015;16:883–5.
   PubMed Web of Science ®Google Scholar
• Beijers AJ, Mols F, Tjan-Heijnen VC, Faber CG, van de Poll-Franse LV, Vreugdenhil G. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry. Acta Oncol. 2015;54:463–9.
   PubMed Web of Science ®Google Scholar
• Stefansson M, Nygren P. Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life. Acta Oncol. 2016;55:1227–35.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Graffman S, Påhlman L, Rimsten Å, Wilander E. Preoperative irradiation with high-dose fractionation in adenocarcinoma of the rectum and rectosigmoid. Acta Radiol Oncol. 1982;21:373–9.
   PubMed Web of Science ®Google Scholar
• Påhlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal carcinoma: a report from a randomized multicenter trial. Ann Surg. 1990;211:187–95.
   PubMed Web of Science ®Google Scholar
• Cedermark B, Johansson H, Rutquist L-E, Wilking N. The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. Cancer. 1995;75:2269–75.
   PubMed Web of Science ®Google Scholar
• Martling A, Holm T, Johansson H, Rutqvist LE, Cedermark B. The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. Cancer. 2001;92:896–902.
   PubMed Web of Science ®Google Scholar
• Pettersson D, Cedermark B, Holm T, Radu C, Pahlman L, Glimelius B, et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg. 2010;97:580–7.
   PubMed Web of Science ®Google Scholar
• Pettersson D, Lorinc E, Holm T, Iversen H, Cedermark B, Glimelius B, et al. Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. Br J Surg. 2015;102:972–8.
   PubMed Web of Science ®Google Scholar
• Breugom AJ, van Gijn W, Muller EW, Berglund A, van den Broek CB, Fokstuen T, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol. 2015;26:696–701.
   PubMed Web of Science ®Google Scholar
• Pach R, Kulig J, Richter P, Gach T, Szura M, Kowalska T. Randomized clinical trial on preoperative radiotherapy 25 Gy in rectal cancer–treatment results at 5-year follow-up. Langenbecks Arch Surg. 2012;397:801–7.
   PubMed Web of Science ®Google Scholar
• Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44.
   PubMed Web of Science ®Google Scholar
• Martin ST, Heneghan HM, Winter DC. Systematic review of outcomes after intersphincteric resection for low rectal cancer. Br J Surg. 2012;99:603–12.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Sgroi G, Sarti E, Barni S. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg. 2016;263:458–64.
   PubMed Web of Science ®Google Scholar
• Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.
   PubMed Web of Science ®Google Scholar
• Lefevre JH, Mineur L, Kotti S, Rullier E, Rouanet P, de Chaisemartin C, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016 Jul 18. [Epub ahead of print]. doi:10:1200/JCO2016.67.6049
   PubMed Web of Science ®Google Scholar
• Evans J, Bhoday J, Sizer B, Tekkis P, Swift R, Perez R, et al. Results of a prospective randomised control 6 vs 12 trial: Is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy? ESMO 2016;Abstr 4520.
   Google Scholar
• Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 2011;29:3753–60.
   PubMed Web of Science ®Google Scholar
• Siddiqui MR, Bhoday J, Battersby NJ, Chand M, West NP, Abulafi AM, et al. Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales. World J Gastroenterol. 2016;22:8414–34.
   PubMed Web of Science ®Google Scholar
• Jakobsen A, Ploen J, Vuong T, Appelt A, Lindebjerg J, Rafaelsen SR. Dose-effect relationship in chemoradiotherapy for locally advanced rectal cancer: a randomized trial comparing two radiation doses. Int J Radiat Oncol Biol Phys. 2012;84:949–54.
   PubMed Web of Science ®Google Scholar
• Appelt AL, Vogelius IR, Ploen J, Rafaelsen SR, Lindebjerg J, Havelund BM, et al. Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost. Int J Radiat Oncol Biol Phys. 2014;90:110–18.
   PubMed Web of Science ®Google Scholar
• Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? J Clin Oncol. 2007;25:4379–86.
   PubMed Web of Science ®Google Scholar
• Braendengen M, Hansson K, Radu C, Siegbahn A, Jacobsson H, Glimelius B. Delineation of gross tumor volume (GTV) for radiation treatment planning of locally advanced rectal cancer using information from MRI or FDG-PET/CT: a prospective study. Int J Radiat Oncol Biol Phys. 2011;81:e439–45.
   PubMed Web of Science ®Google Scholar
• Radu C, Norrlid O, Braendengen M, Hansson K, Isacsson U, Glimelius B. Integrated peripheral boost in preoperative radiotherapy for the locally most advanced non-resectable rectal cancer patients. Acta Oncol. 2013;52:528–37.
   PubMed Web of Science ®Google Scholar
• Juul T, Ahlberg M, Biondo S, Espin E, Jimenez LM, Matzel KE, et al. Low anterior resection syndrome and quality of life: an international multicenter study. Dis Colon Rectum. 2014;57:585–91.
   PubMed Web of Science ®Google Scholar
• Chen TY, Wiltink LM, Nout RA, Meershoek-Klein Kranenbarg E, Laurberg S, Marijnen CA, et al. Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial. Clin Colorectal Cancer. 2015;14:106–14.
   PubMed Web of Science ®Google Scholar
• Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711–17.
   PubMed Web of Science ®Google Scholar
• Gerard JP, Frin AC, Doyen J, Zhou FX, Gal J, Romestaing P, et al. Organ preservation in rectal adenocarcinoma (T1) T2-T3 Nx M0. Historical overview of the Lyon Sud - Nice experience using contact X-ray brachytherapy and external beam radiotherapy for 120 patients. Acta Oncol. 2015;54:545–51.
   PubMed Web of Science ®Google Scholar
• Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29:4633–40.
   PubMed Web of Science ®Google Scholar
• Maas M. Rectal cancer: are we ready for a paradigm shift? Thesis. Maastricht: Datawyse/University Pers Maastricht; 2013.
   Google Scholar
• Hall MD, Schultheiss TE, Smith DD, Fakih MG, Wong JY, Chen YJ. Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy. Acta Oncol. 2016;55:1392–9.
   PubMed Web of Science ®Google Scholar
• Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum. 2010;53:1692–8.
   PubMed Web of Science ®Google Scholar
• Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16:957–66.
   PubMed Web of Science ®Google Scholar
• Appelt AL, Ploen J, Harling H, Jensen FS, Jensen LH, Jorgensen JC, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16:919–27.
   PubMed Web of Science ®Google Scholar
• Joye I, Debucquoy A, Fieuws S, Wolthuis A, Sagaert X, D’Hoore A, et al. Can clinical factors be used as a selection tool for an organ-preserving strategy in rectal cancer? Acta Oncol. 2016;55:1047–52.
   PubMed Web of Science ®Google Scholar
• Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol. 2012;30:1620–7.
   PubMed Web of Science ®Google Scholar
• Hughes R, Harrison M, Glynne-Jones R. Could a wait and see policy be justified in T3/4 rectal cancers after chemo-radiotherapy? Acta Oncol. 2010;49:378–81.
   PubMed Web of Science ®Google Scholar
• Poulsen LO, Qvortrup C, Pfeiffer P, Yilmaz M, Falkmer U, Sorbye H. Review on adjuvant chemotherapy for rectal cancer - why do treatment guidelines differ so much? Acta Oncol. 2015;54:437–46.
   PubMed Web of Science ®Google Scholar
• Glimelius B. Adjuvant chemotherapy for patients with rectal cancer -- will the controversy be resolved? Acta Oncol. 2015;54:433–6.
   PubMed Web of Science ®Google Scholar
• Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16:200–7.
   PubMed Web of Science ®Google Scholar
• Bujko K, Glimelius B, Valentini V, Michalski W, Spalek M. Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: a meta-analysis of randomized trials comparing surgery +/− a fluoropyrimidine and surgery + a fluoropyrimidine +/− oxaliplatin. Eur J Surg Oncol. 2015;41:713–23.
   PubMed Web of Science ®Google Scholar
• Petersen SH, Harling H, Kirkeby LT, Wille-Jorgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev. 2012;3:CD004078.
   PubMed Web of Science ®Google Scholar
• Bujko K, Wyrwicz L, Rutkowski A, Malinowska M, Pietrzak L, Krynski J, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27:834–42.
   PubMed Web of Science ®Google Scholar
• Nilsson PJ, van Etten B, Hospers GAP, Påhlman L, van de Velde CJH, Beets-Tan RGH, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer – the RAPIDO trial. BMC Cancer. 2013;13:279.
   PubMed Web of Science ®Google Scholar
• Gasinska A, Skolyszewski J, Popiela T, Richter P, Darasz Z, Nowak K, et al. Bromodeoxyuridine labeling index as an indicator of early tumor response to preoperative radiotherapy in patients with rectal cancer. J Gastrointest Surg. 2007;11:520–8.
   PubMed Web of Science ®Google Scholar
• Perez RO, Habr-Gama A, Sao Juliao GP, Gama-Rodrigues J, Sousa AH Jr, Campos FG, et al. Optimal timing for assessment of tumor response to neoadjuvant chemoradiation in patients with rectal cancer: do all patients benefit from waiting longer than 6 weeks? Int J Radiat Oncol Biol Phys. 2012;84:1159–65.
   PubMed Web of Science ®Google Scholar